Trial results

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

NCT07282613 on ClinicalTrials.gov · last registry update 2026-09-09

A small phase 3 — 80 participants, against a typical 424. Due to report 7 September 2029, alongside 12 other tracked readouts that quarter. Primary outcome, as filed: Change in glycated haemoglobin (HbA1c). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

RECRUITING

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

80

Started

2026-08-04

Primary completion

2029-09-07 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change in glycated haemoglobin (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.